Bronchopulmonary dysplasia: Then and now

Neonatology

Volumn 102, Issue 1, 2012, Pages 1-8

  Philip, Alistair G S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Assisted ventilation; Bronchopulmonary dysplasia; Chronic lung disease; Oxygen; Prematurity

Indexed keywords

BETAMETHASONE; BOSENTAN; CAFFEINE; NITRIC OXIDE; OXYGEN; OXYGEN RADICAL; PROSTACYCLIN; RETINOL; SILDENAFIL; SURFACTANT;

ARTICLE; ASSISTED VENTILATION; BRONCHIOLITIS; CHORIOAMNIONITIS; CLINICAL FEATURE; FLUID INTAKE; GENETIC PREDISPOSITION; GESTATIONAL AGE; HISTOPATHOLOGY; HUMAN; LUNG DYSPLASIA; LUNG FIBROSIS; MALNUTRITION; NEWBORN; OXYGEN THERAPY; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL; SEPSIS;

BRONCHOPULMONARY DYSPLASIA; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; OXYGEN; RESPIRATION, ARTIFICIAL;

EID: 84857131115     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000336030     Document Type: Article

References (58)

1. Northway WH Jr, Rosan RC, Porter DY: Pulmonary disease following respirator therapy of hyaline membrane disease: bronchopulmonary dysplasia. N Engl J Med 1967; 276: 357-368.
2. Hawker JM, Reynolds EOR, Taghizadeh A: Pulmonary surface tension and pathological changes in infants dying after respirator treatment for severe hyaline membrane disease. Lancet 1967;ii:75-77.
3. Kaplan HP, Robinson FR, Kapanci Y, Weibel ER: Pathogenesis and reversibility of the pulmonary lesions of oxygen toxicity in monkeys. 1. Clinical and light microscopic studies. Lab Invest 1969; 20: 94-100.
4. Wilson MJ, Mikity VG: A new form of respiratory disease in premature infants. Am J Dis Child 1960; 99: 489-499.
5. Philip AGS: Chronic lung disease of prematurity: a short history. Semin Fetal Neonatal Med 2009; 14: 333-338.
6. Hodgman JE: Relationship between Wilson- Mikity syndrome and the new bronchopulmonary dysplasia. Pediatrics 2003; 112: 1414-1415.
7. Philip AGS: Oxygen plus pressure plus time: the etiology of bronchopulmonary dysplasia. Pediatrics 1975; 55: 45-50.
8. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T: Artificial surfactant therapy in hyaline membrane disease. Lancet 1980;i:55-59.
9. Jobe AJ: The new BPD: an arrest of lung development. Pediatr Res 1999; 46: 641-643.
10. Nelson NM: Chronology, morphology and physiology of pulmonary oxygen toxicity; in Lucey JFed): Problems of Neonatal Intensive Care Units. Report of the 59th Ross Conference on Pediatric Research. Columbus, Ross Laboratories, 1969, p 44.
11. Pusey VA, MacPherson RI, Chernick V: Pulmonary fibroplasia following prolonged artificial ventilation of newborn infants. Can Med Assoc J 1969; 100: 451-457.
12. Liggins GC, Howie RN: A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50: 515-525.
13. McCarthy MUS: Recommendations for antenatal corticosteroids. Lancet 1994; 343: 726.
14. Jobe AH, Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723-1729.
15. Walsh MC, Yao Q, Gettner PP, Hale E, Collins M, Hensman A, Everette R, Peters N, Miller N, Muran G, Auten K, Newman N, Rowan G, Grisby C, Arnell K, Miller L, Ball B, McDavid G; National Institute of Child Health and Human Development Neonatal Research Network: Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004; 114: 1305-1311.
16. Coalson JJ: Pathology of new bronchopulmonary dysplasia. Semin Neonatol 2003; 8: 73-81.
17. Pfister RH, Soll RF: Pulmonary care and adjunctive therapies for prevention and amelioration of bronchopulmonary dysplasia. Neoreviews 2011; 12:e635-e643.
18. Spence KL, Zozobrado JC, Patterson BW, Hamvas A: Substrate utilization and kinetics of surfactant metabolism in evolving bronchopulmonary dysplasia. J Pediatr 2005; 147: 480-485.
19. Guttentag S, Foster CD: Update in surfactant therapy. Neoreviews 2011; 12: 625-633.
20. Saugstad OD: Oxygen radicals and pulmonary damage. Pediatr Pulmonol 1985; 1: 167-175.
21. Speer CP, Halliday HL: Ola Didrik Saugstad - an oxygen radical. Neonatology 2008; 94: 188-189.
22. Escobar J, Cernada M, Vento M: Oxygen and oxidative stress in the neonatal period. Neoreviews 2011; 12: 613-623.
23. Brown ER, Stark A, Sosenko I, Lawson EE, Avery ME: Bronchopulmonary dysplasia: possible relationship to pulmonary edema. J Pediatr 1978; 92: 982-984.
24. Watterberg KL, Carmichael DF, Gerdes JS, Werner S, Backstrom C, Murphy S: Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J Pediatr 1994; 125: 264-269.
25. Watterberg KL, Demers LM, Scott SM, Murphy S: Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996; 97: 210-215.
26. Speer CP: Inflammation and bronchopulmonary dysplasia. Semin Neonatol 2003; 8: 29-38.
27. Bose CL, Dammann CE, Laughon MM: Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. Arch Dis Child Fetal Neonatal Ed 2008; 93:F455-F461.
28. Viscardi RM, Muhumuza CK, Rodriguez A, Fairchild KD, Sun CC, Gross GW, Campbell AB, Wilson PD, Hester L, Hasday JD: Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurological outcomes in preterm infants. Pediatr Res 2004; 55: 1009-1017.
29. Thomas W, Speer CP: Chorioamnionitis: important risk factor or innocent bystander for neonatal outcome? Neonatology 2011; 99: 177-187.
30. Katzenstein A, Davis C, Braude A: Pulmonary changes in neonatal sepsis due to group B beta-hemolytic streptococcus: relation to hyaline membrane disease. J Infect Dis 1976; 133: 430-435.
31. Frank L, Sosenko IR: Undernutrition as a major contributing factor in the pathogenesis of bronchopulmonary dysplasia. Am Rev Respir Dis 1988; 138: 725-729.
32. Wilson DC, McClure G, Halliday HL, Reid MM, Dodge JA: Nutrition and bronchopulmonary dysplasia. Arch Dis Child 1991; 66: 37-38.
33. Bose CL, van Marter LJ, Laughon MM, O'Shea TM, Allred EN, Karna P, Ehrenkranz RA, Boggess K, Leviton A; Extremely Low Gestational Age Newborn Study Investigators: Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. Pediatrics 2009; 124:e450-e458.
34. Clark DA, Pincus LG, Oliphant M, Hubbell C, Oates RP, Davey FR: HLA-A2 and chronic lung disease in neonates. J Am Med Assoc 1982; 248: 1868-1869.
35. Bhandari V, Gruen JR: The genomics of bronchopulmonary dysplasia. Neoreviews 2007; 8:e336-e344.
36. Abman SH, Mourani PM, Sontag M: Bronchopulmonary dysplasia: a genetic disease. Pediatrics 2008; 122: 658-659.
37. Merritt TA, Deming DD, Boynton BR: The 'new' bronchopulmonary dysplasia: challenges and commentary. Semin Fetal Neonatal Med 2009; 14: 345-357.
38. Avery ME, Tooley WH, Keller JE, et al: Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 1987; 79: 26-30.
39. Shenai JP, Kennedy KA, Chytil F, Stahlman MT: Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr 1987; 111: 269-277.
40. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA: Vitamin A supplementation for extremely low birth weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999; 340: 1962-1968.
41. Doi T, Sugimoto K, Puri P: Prenatal retinoic acid up-regulates pulmonary gene expression of COUP-TFll, FOG2 and GATA4 in pulmonary hypoplasia. J Pediatr Surg 2009; 44: 1933-1937.
42. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group: Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354: 2112-2121.
43. Schmidt B, Roberts R, Miller D, Kirpalani H: Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very low birth-weight infants. Neonatology 2008; 93: 284-287.
44. van Marter LJ, Leviton A, Kuban KCK: Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia. Pediatrics 1990; 86: 331-336.
45. Mammel MC, Green TP, Johnson DE, Thompson TR: Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983;i:1356-1358.
46. Avery GB, Fletcher AB, Kaplan M, Brudno DS: Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics 1985; 75: 106-111.
47. Cummings JJ, D'Eugenio DB, Gross SJ: A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989; 320: 1505-1510.
48. Durand M, Sardesai S, McEvoy C: Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized controlled trial. Pediatrics 1995; 95: 584-590.
49. Stark AR: Risks and benefits of post-natal corticosteroids. Neoreviews 2005; 6:e99-e103.
50. Doyle LW, Ehrenkranz RA, Halliday HL: Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010; 98: 217-224.
51. Doyle LW, Ehrenkranz RA, Halliday HL: Dexamethasone treatment after the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010; 98: 289-296.
52. Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F: Mortality, severe respiratory distress syndrome and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics 1997; 100:E4.
53. Speer CP: Neonatal respiratory distress syndromeRDS): an inflammatory disease? Neonatology 2011; 99: 316-319.
54. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A, Poole WK, Schibler K, Newman NS, Ambalavanan N, Frantz ID 3rd, Piazza AJ, Śnchez PJ, Morris BH, Laroia N, Phelps DL, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran V, Sood BG, O'Shea TM, Bell EF, Ehrenkranz RA, Watterberg KL, Higgins RD: Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010; 362: 1959-1969.
55. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC, Null DR, Hudak ML, Puri AR, Golombek SG, Courtney SE, Stewart DL, Welty SE, Phibbs RH, Hibbs AM, Luan X, Wadlinger SR, Asselin JM, Coburn CE; NO CLD Study Group: Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355: 343-353.
56. Mercier JC, Hummler H, Durrmeyer X, Sanchez- Luna M, Carnielli V, Field D, Greenough A, Van Overmeire B, Jonsson B, Hallman M, Baldassarre J; EUNO Study Group: Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babiesEUNO): a randomized controlled trial. Lancet 2010; 376: 346-354.
57. Abman SH: Pulmonary vascular disease and bronchopulmonary dysplasia: evaluation and treatment of pulmonary hypertension. Neoreviews 2011; 12:e645-e650.
58. Alphonse RS, Thébaud B: Growth factors, stem cells and bronchopulmonary dysplasia. Neonatology 2011; 99: 326-337.